People with atrial fibrillation and Alzheimer’s disease who received NOACs showed a modestly slower rate of cognitive decline. For people living with both Alzheimer’s disease and atrial fibrillation, the type of blood-thinning medication they receive may be linked to how quickly their cognitive abilities decline. Research from Karolinska Institutet, published in the European Heart Journal, […]This is a curated summary.